Vitality Watch

Dossier pubmed meta analysis 07-apr-2026
Systematic review or meta-analysis of multiple human studies

Hypnotic-Induced Fall Risk Upon Awakening: A Network Meta-Analysis of Postural Stability Outcomes.

Key claim: A network meta-analysis of 23 RCTs found most in-label hypnotic doses do not significantly impair morning postural stability versus placebo, but zopiclone 7.5 mg and higher-dose or extended-release zolpidem worsen balance especially at middle-of-the-night awakening and in older adults.

Abstract

Chronic insomnia affects 10% of adults, with hypnotic medications widely prescribed. Residual pharmacological effects upon awakening may affect postural stability, increasing fall risk. We used a Network Meta-Analysis (NMA) framework to compare the influence of hypnotic medications on posture upon awakening. A systematic review and frequentist random-effects NMA was conducted following the PRISMA guidelines and a pre-determined protocol. We searched PubMed, EMBASE, ClinicalTrials.gov, WHO-ICTRP for randomized controlled trials until 10/21/2025, documenting the effects of hypnotics on static (body sway) and dynamic (walking test) balance. Risk-of-bias and confidence in evidence were assessed with RoB2 and CINeMA. Of 4459 identified records, 23 studies were included in the review. Most in-label doses of hypnotics showed no significant impact on postural stability in the morning compared to placebo, except zopiclone 7.5 mg both at bedtime (Standardized Mean Difference-SMD = 0.22, 95% C.I.[0.22;0.1.24]) and middle-of-the-night awakening (SMD = 4.45, 95% C.I.[3.54;5.36]), while zolpidem 6.5 mg extended-release proved worse in the subset including older adults (SMD = 0.39, 95% C.I.[0.01;0.76]). Same applied to middle-of-the-night evaluations for zopiclone 7.5 mg (SMD = 0.98, 95% C.I.[0.07;1.90]), zolpidem 6.5 mg extended-release (SMD = 1.14, 95% C.I.[0.30;1.98]), and zolpidem 10 mg (SMD = 1.60, 95% C.I.[0.63;2.58]). Confidence in the evidence was mainly low/very-low. Most regulatory-approved hypnotics did not significantly impair postural balance at in-label doses. However, caution is warranted for longer-acting and high-doses, particularly in high fall-risk individuals, including older adults. Given the age-related decline in postural reflexes and heightened sensitivity to CNS depressants, lower doses and shorter half-life drugs should be preferred whenever hypnotic therapy is necessary. Future research is needed to explore dynamic balance further to optimize prescribing guidelines for fall prevention in vulnerable populations.

Why this matters

Hypnotic prescribing in older adults is dominated by residual-sedation and fall-risk trade-offs, and until now most data were drug-by-drug rather than comparative. A network meta-analysis of postural-stability RCTs produces a residual-balance ranking across agents, isolating zopiclone 7.5 mg and higher-dose or extended-release zolpidem as the outliers while flagging middle-of-the-night awakening as the high-risk window. Confidence is mostly low/very-low and these are acute postural-sway markers, not fall-outcome trials.

Source

Link

Briefing card

Hypnotic-Induced Fall Risk Upon Awakening: A Network Meta-Analysis of Postural Stability Outcomes.
Stage: meta analysis · pubmed · 07-apr-2026

If you are an older adult taking zopiclone 7.5 mg or extended-release/higher-dose zolpidem, this analysis found measurably worse balance on awakening — especially mid-night — than with other in-label hypnotic options.

A network meta-analysis of 23 RCTs found most in-label hypnotic doses do not significantly impair morning postural stability versus placebo, but zopiclone 7.5 mg and higher-dose or extended-release zolpidem worsen balance especially at middle-of-the-night awakening and in older adults.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/jsr.70337

build build 880 · 2bcef25 · 2026-11-18